Willow Biosciences Inc (WLLW) AI Stock Analysis

• Market Cap: $9.27M
• Dividend Yield: N/A
• Average Volume (3M): 87.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.48
• Revenue Growth: 571.23%
• EPS Growth: 64.25%
• Country: CA
• Employees: 19
• Sector: Healthcare
• Sector Strength: 39
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 352,222,660
• 10 Day Avg. Volume: 116,843
• 30 Day Avg. Volume: 87,404
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.87
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.98
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: $0.50 ▲(56.25%Upside)

Willow Biosciences Inc, now transitioning to Atlas Energy Corp, is undergoing significant changes. While the company's recapitalization and strategic rebranding are positive indicators for future growth, its current financial instability remains a major concern. Technical indicators suggest some short-term bullish momentum, but valuation challenges persist due to negative earnings.

Willow Biosciences Inc Business Overview & Revenue Model

Company Description

Willow Biosciences Inc. is a biotechnology company that operates in the field of synthetic biology. The company focuses on the production of high-purity, plant-derived compounds that are used in various industries including pharmaceuticals, consumer packaged goods, and personal care products. Using advanced biosynthetic methods, Willow Biosciences aims to provide sustainable and cost-effective alternatives to traditional production methods.

How the Company Makes Money

Willow Biosciences Inc. generates revenue primarily through the development and commercialization of biosynthetically produced cannabinoids. The company uses its proprietary yeast-based fermentation platform to produce cannabinoids at scale, offering a sustainable and consistent supply of these compounds. Revenue streams include the sale of cannabinoids to pharmaceutical companies, consumer product manufacturers, and other industries that utilize these compounds in their products. Additionally, Willow Biosciences may engage in strategic partnerships and licensing agreements to further monetize its proprietary technology and expand its market reach.

Willow Biosciences Inc Financial Statement Overview

Summary

Despite strong revenue growth of 297.8%, Willow Biosciences Inc faces significant financial challenges, including sustained losses, negative equity, and liquidity constraints. The company's financials indicate high risk and instability, overshadowing operational improvements.

Income Statement

Willow Biosciences Inc has shown a significant increase in revenue from $1,172,000 in 2023 to $4,662,000 in 2024, representing a strong revenue growth rate of 297.8%. However, the company continues to experience substantial losses reflected in negative net profit margins and EBIT margins. The recent gross profit margin of 100% in 2024 is an improvement, indicating better cost management, though overall profitability remains a major concern.

Balance Sheet

The balance sheet highlights a concerning negative stockholders' equity of -$505,000 in 2024, a sharp decline from $3,436,000 in 2023, indicating solvency issues. The debt-to-equity ratio is not applicable due to negative equity, and the equity ratio has shifted unfavorably. These factors point to high financial risk and instability.

Cash Flow

Operating cash flow remains negative, with a slight improvement in free cash flow from -$11,539,000 in 2023 to -$3,743,000 in 2024. Despite this improvement, the free cash flow to net income ratio remains unfavorable, highlighting ongoing liquidity challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.66M	1.17M	821.00K	133.00K	10.00K
Gross Profit	3.28M	-659.00K	-6.65M	-11.40M	10.00K
EBITDA	-4.54M	-11.06M	-12.09M	-2.92M	-30.72M
Net Income	-6.19M	-13.03M	-14.81M	-6.17M	-33.99M
Balance Sheet
Total Assets	2.49M	6.67M	18.15M	35.02M	21.86M
Cash, Cash Equivalents and Short-Term Investments	353.00K	3.17M	15.03M	30.12M	15.89M
Total Debt	1.97M	2.16M	664.00K	802.00K	869.00K
Total Liabilities	2.99M	3.24M	1.77M	5.33M	22.42M
Stockholders Equity	-505.00K	3.44M	16.37M	29.68M	-559.00K
Cash Flow
Free Cash Flow	-3.74M	-11.54M	-14.54M	-19.99M	-13.78M
Operating Cash Flow	-3.72M	-10.92M	-13.86M	-18.23M	-12.78M
Investing Cash Flow	78.00K	3.46M	-4.55M	-1.67M	-837.00K
Financing Cash Flow	786.00K	-318.00K	-723.00K	34.13M	9.89M

Willow Biosciences Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.32
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:WLLW, the sentiment is Positive. The current price of 0.32 is above the 20-day moving average (MA) of 0.19, above the 50-day MA of 0.15, and above the 200-day MA of 0.30, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 58.75 is Neutral, neither overbought nor oversold. The STOCH value of 56.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:WLLW.

Willow Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WLLW	52 Neutral	$9.27M	―	-971.43%	―	571.23%	64.25%
Sector *	49 Neutral	AU$2.50B	4.42	-64.25%	2.77%	36.51%	13.14%
OVAT	39 Underperform	C$1.76M	―	62.01%	―	35.35%	31.85%
CVGR	20 Underperform	$913.63K	―	49.80%	―	-100.00%	-42.50%

Willow Biosciences Inc Corporate Events

Atlas Energy Corp. Completes Transformative Recapitalization

Atlas Energy Corp., formerly Willow Biosciences Inc., has completed a transformative recapitalization, including a $30 million private placement, a new management team, and a name change. The company plans to leverage its strong shareholder base to explore high-quality royalty and streaming opportunities globally, marking a significant milestone in its mission to provide innovative capital solutions in the energy industry.

Willow Biosciences Inc. Receives Conditional TSXV Listing Approval

Willow Biosciences Inc. has received conditional acceptance to list its common shares on the TSX Venture Exchange (TSXV) under the TSXV Sandbox Program. This transition involves a name change to ‘Atlas Energy Corp.’ and a share consolidation, with trading expected to commence on June 24, 2025. The company aims to meet specific exit conditions within 12 months, including completing a $30 million private placement and investing in qualifying projects, to maintain its listing status.

Willow Biosciences to Transform into Atlas Energy Corp. with New Strategic Focus

Willow Biosciences Inc. announced a significant restructuring plan involving a C$30 million private placement, a new executive team, and a rebranding to ‘Atlas Energy Corp.’ The company aims to transition into an international upstream royalty and streaming company focused on oil and gas transactions, with plans to list on the TSX Venture Exchange under the new name and symbol. This strategic shift marks a major pivot from its previous operations, potentially impacting its market positioning and stakeholder interests.

Willow Biosciences Secures $30 Million in Recapitalization Effort

Willow Biosciences Inc. has secured $30 million in firm commitments for a non-brokered private placement, exceeding initial demand. This recapitalization effort is contingent on certain conditions, including TSX Venture Exchange approval and a share consolidation. The company plans to hold a special shareholder meeting to approve these changes, positioning itself for future growth in the oil and gas sector.

Willow Biosciences Announces Recapitalization and Rebranding to Atlas Energy Corp.

Willow Biosciences Inc. has announced a $30 million recapitalization financing, along with a reorganization that includes a new executive team and board of directors, as it transitions to Atlas Energy Corp. The company aims to list on the TSX Venture Exchange and will focus on international upstream oil and gas royalty and streaming opportunities. The new leadership team, with extensive experience in the industry, is expected to drive growth and value creation, leveraging their history of successful ventures in the oil and gas sector.

Willow Biosciences Sells Subsidiary, Implements Management Changes

Willow Biosciences Inc. has completed the sale of its operating subsidiary, Epimeron USA, Inc., to Mycofeast Ltd.’s U.S. subsidiary for $2.76 million. This transaction, which includes management changes, will allow Willow to reduce debt and explore future opportunities, potentially enhancing shareholder value.

Willow Biosciences Reports Key Shareholder Meeting Outcomes

Willow Biosciences Inc. announced the results of its annual general and special meeting, where shareholders approved several key resolutions, including the election of five directors and the appointment of KPMG LLP as the company’s auditor. Additionally, shareholders authorized the sale of Epimeron USA, Inc., and a potential name change for the corporation. These decisions reflect strategic moves to streamline operations and potentially rebrand, indicating a focus on future growth and adaptation in the industry.